Rgenta Therapeutics scores $20m seed

Cambridge, Massachusetts-based Rgenta Therapeutics, a developer of RNA-targeting medicines, has secured $20 million in seed funding.

2 April 2020•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles